Tempus AI (NASDAQ:TEM) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group initiated coverage on shares of Tempus AI (NASDAQ:TEM) in a report issued on Monday, Marketbeat Ratings reports. The brokerage issued an underperform rating and a $35.00 target price on the stock.

A number of other equities research analysts have also recently weighed in on TEM. BTIG Research reduced their price target on shares of Tempus AI from $105.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Needham & Company LLC reissued a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a research report on Wednesday, March 11th. Stifel Nicolaus set a $60.00 price target on shares of Tempus AI in a research report on Wednesday, February 25th. Robert W. Baird began coverage on shares of Tempus AI in a research note on Tuesday, February 17th. They issued an “outperform” rating and a $59.00 price objective on the stock. Finally, Canaccord Genuity Group dropped their price objective on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, December 22nd. Nine investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Tempus AI presently has an average rating of “Moderate Buy” and an average target price of $71.36.

Tempus AI Price Performance

Shares of TEM opened at $56.41 on Monday. Tempus AI has a 1-year low of $39.01 and a 1-year high of $104.32. The stock has a market cap of $10.08 billion, a PE ratio of -40.01 and a beta of 4.90. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The firm has a fifty day moving average price of $50.78 and a 200 day moving average price of $66.28.

Insider Activity

In other Tempus AI news, CEO Ryan Fukushima sold 9,592 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $566,407.60. Following the completion of the sale, the chief executive officer directly owned 694,354 shares of the company’s stock, valued at $41,001,603.70. This represents a 1.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James William Rogers sold 10,084 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $595,460.20. Following the sale, the chief financial officer directly owned 101,166 shares of the company’s stock, valued at approximately $5,973,852.30. This represents a 9.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 563,841 shares of company stock worth $32,258,311 over the last quarter. 26.27% of the stock is owned by insiders.

Institutional Investors Weigh In On Tempus AI

Institutional investors have recently added to or reduced their stakes in the business. Renaissance Capital LLC raised its position in Tempus AI by 26.9% in the third quarter. Renaissance Capital LLC now owns 84,166 shares of the company’s stock worth $6,793,000 after acquiring an additional 17,866 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Tempus AI by 1,459.8% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 101,276 shares of the company’s stock worth $8,174,000 after purchasing an additional 94,783 shares during the period. Hussman Strategic Advisors Inc. purchased a new position in shares of Tempus AI in the 3rd quarter valued at about $1,695,000. Vanguard Group Inc. lifted its stake in shares of Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after purchasing an additional 1,706,837 shares during the period. Finally, Krane Funds Advisors LLC lifted its stake in shares of Tempus AI by 218.2% in the third quarter. Krane Funds Advisors LLC now owns 28,230 shares of the company’s stock valued at $2,427,000 after purchasing an additional 19,358 shares during the period. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Key Headlines Impacting Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus announced a commercial expansion with Predicta Biosciences to market a co‑branded ultrasensitive whole‑genome sequencing assay (GenoPredicta) for hematologic malignancies and MRD monitoring — a direct revenue/market‑access catalyst for Tempus’ oncology genomics business. Tempus AI Shares Gain on Commercial Partnership With Predicta Biosciences
• Positive Sentiment: Reports show unusual options activity: ~32,895 call options bought (≈+68% vs. average), indicating short‑term bullish positioning from traders. Elevated call volume often amplifies intraday upside. Options volume report
• Positive Sentiment: TD Cowen raised its rating to Buy, providing a fresh broker upgrade that can attract buyers and support momentum. Tempus AI (NASDAQ:TEM) Raised to “Buy” at TD Cowen
• Positive Sentiment: Tempus had 31 abstracts (including one oral presentation) accepted for AACR 2026 — scientific validation and data visibility often boost investor confidence in commercial and partnership prospects. Tempus Announces 31 Abstracts for Presentation at the American Association for Cancer Research Annual Meeting 2026
• Positive Sentiment: New product/service visibility (an “Active Follow‑Up” workflow and management appearances at the Needham conference) has increased investor attention on Tempus’ clinical workflow monetization and commercialization story. Tempus AI jumps as investors focus on new “Active Follow-Up” workflow and Needham conference visibility
• Neutral Sentiment: Mizuho reaffirmed its Buy rating — supportive but not a new bullish signal. Mizuho Securities Keeps Their Buy Rating on Tempus AI, Inc. Class A (TEM)
• Negative Sentiment: Jefferies initiated coverage with an Underperform (contrary to other upgrades), which can pressure sentiment among longer‑term investors. Jefferies initiates coverage of Tempus AI (TEM) with underperform recommendation
• Negative Sentiment: Market write‑ups note extensive insider selling activity over recent months, a potential long‑term governance/flow concern that can cap the stock’s multiple. QuiverQuant coverage noting insider sales

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.